Clinical trials: Specific Immunotherapy
Rhinitis, Allergic, Respiratory Tract Infections
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their…
- Conditions
- Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma
- Trial name
- NCT04389034
- Testing
- Pollinex Quattro with tree- and grass pollen extracts and their mixtures
- Where
- Germany
- Volunteers
- 113 people
- Sponsor
- Allergy Therapeutics
Hay Fever
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5…
- Trial name
- NCT01506375
- Testing
- gpASIT+TM, gpASIT+TM + adjuvant
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- BioTech Tools S.A.
Solid Tumors, Advanced Cancer
Personalized Neoantigen Peptide Vaccines for Solid Tumors
This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors.
- Conditions
- Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy
- Trial name
- NCT07002203
- Testing
- Personalized Neoantigen Peptide Vaccine
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Seqker Biosciences, Inc.
Aerodigestive Precancerous Lesions and Malignancies
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated…
- Trial name
- NCT02241369
- Testing
- INO-3106, INO-9012
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Inovio Pharmaceuticals
Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC)
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults…
- Conditions
- Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
- Trial name
- PSMA-013-001 (NCT07813637)
- Testing
- JANX013, JANX007
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Janux Therapeutics
Neoplasms, Breast
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer.
- Trial name
- INDUCT (NCT01220128)
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Aromatase inhibitor, 5-Fluorouracil
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Allergic Rhinoconjunctivitis
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
The purpose of this study is to find out if rBet v1-FV works to relieve Seasonal Allergic Rhinitis symptoms compared to Placebo (an inactive substance that looks like rBet v1-FV and also contains Aluminum Hydroxide but does not…
- Trial name
- NCT01490411
- Testing
- rBet v1-FV
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Allergopharma GmbH & Co. KG
Pollen Allergy
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
The aim of this clinical trial is to show safety and efficacy of the allergoid preparation of birch pollen allergens in the treatment of birch allergic patients in a representative number of patients.
- Trial name
- NCT00263627
- Testing
- Birch pollen allergoid
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- Allergopharma GmbH & Co. KG
Grass Pollen Allergy
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture
- Trial name
- NCT00264459
- Testing
- Grass pollen formulation, Comparator
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Allergopharma GmbH & Co. KG
Seasonal Allergic Rhinoconjunctivitis
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.
- Trial name
- NCT00813046
- Testing
- gpASIT+TM
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- BioTech Tools S.A.
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
The purpose of this study is to evaluate the clinical activity and safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-induction therapy in adult patients with WT1-positive AML presenting a suboptimal…
- Trial name
- NCT01051063
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma
DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- NCT04792489
- Testing
- zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine
- Where
- 32 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- Miltenyi Biomedicine GmbH
Birch Pollen Allergy
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
- Trial name
- NCT00266526
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.
- Trial name
- NCT01012531
- Testing
- Subcutaneous injections with highly polymerized allergen extract
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Roxall Medizin
Lymphoma, Extranodal NK-T-Cell, EBV
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
- Trial name
- CITADEL (NCT01948180)
- Testing
- baltaleucel-T
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Cell Medica Ltd
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Ragweed MATA MPL
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis…
- Trial name
- NCT00423787
- Testing
- Ragweed MATA MPL
- Where
- 76 sites in United States, Canada
- Volunteers
- 993 people
- Sponsor
- Allergy Therapeutics
Bee Venom Allergy
Efficacy and Safety of a Purified Standardised Bee Venom Preparation
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy
- Trial name
- NCT00263952
- Testing
- bee venom
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
This is a prospective open label, controlled, randomized study to test the safety and efficacy of active specific immunotherapy with tecemotide (L-BLP25) for the treatment of subjects with Stage IIIB or Stage IV non-small cell…
- Trial name
- NCT00157209
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC)
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118612
- Testing
- Tree MATA MPL - Therapeutic Regimen, Tree MATA MPL - Intermediate dose, Tree MATA MPL - Low dose
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics